China: Pfizer pill will be used under conditions

The United States, the European Union and 40 other countries have authorized the use of the Paxlovid pill

The consumption of the pill against Covid-19 from the American company Pfizer has been authorized in China. This decision was made by China's drug regulator, as foreign vaccines are awaited in the country.

Paxlovid is the commercial name of the oral treatment. In the European Union, the United States and 40 other countries, it was authorized at the end of December.

As a result, certain studies showed that the pills significantly reduce the cases of hospitalizations and death, of patients with serious risk. Most likely, it is functional in terms of the omicron variant.

These antivirals are capable of reducing the replication of the disease, since it stops it in its entirety.

These tablets will be reserved for those patients who possibly develop Covid. This measure was taken by China and all countries where the supply is authorized.

The Chinese regulator indicated in a statement on its website that Pfizer will continue with the studies regarding the pills, and then present said results.

For several weeks, China has maintained outbreaks of infection, which is why they made this decision. Although there are few outbreaks, the authorities are in charge of the cases, mostly omicron.

In this country, a strategy called “Zero Covid” has been applied since the pandemic began. In this way measures are taken to prevent the spread of cases. This Saturday the Ministry of Health announced that there were 40 new cases nationwide.

Celebration of the 2022 Winter Olympics

The government decided to increase surveillance in Beijing, due to the celebration of the 2020 Winter Olympics, which will end on February 20.

The participants of the event are confined in a hermetic sanitary bubble, where they cannot have contact with the rest of the people.

For now, China has not issued any authorization regarding foreign vaccines, only locally manufactured ones being accepted. The ones that are most in demand are Sinovac and Sinopharm.

At the end of January, there was a vaccination rate for both doses of more than 90% of the population in the country. Being a total of 3,030 million vaccines in the country, according to information from the Chinese Ministry of Health.

Sinovac reported that he wants to create a specific dose against the omicron variant, since there are doubts about the efficacy of new variants.